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Bladder cancer ranked 13 among the most common cancer diagnosis in Saudi Arabia, affecting 3.6/100,000 men and 1/100,000 women. In 2010, there were an estimated 243 new cases of bladder cancer accounting for 2.5% of all newly diagnosed cases. It affected 193 (78.4%) males and 50 (21.6%) females with a male:female ratio of 385:100. The most common histological subtypes is transitional cell carcinoma (82%) followed by squamous cell carcinoma (4%). [1] 1. Staging: [2] Appendix I. 2. Grading: The World Health Organization grading of urinary tumors 2004 [3] will be used as follow: 2. [4] [5] [6] Evidence Level -3 (EL-3). 3.1.3.1.4. Second TURBT is recommended to be done within 2-4 weeks from initial resection in the following conditions: [7] [8] [9] (EL-2) 3. [12] 3.1.6. Low-risk NMIBC (low-grade Ta with tumor size <3 cm). 3.1.7. Intermediate risk NMIBC (low-grade Ta with either multifocal disease or with tumor size >3 cm or recurrence at 3 months). 3.1.8. High-risk NMIBC (high-grade Ta, all T1, CIS). 3.1.9. Utilization of nomograms and risk calculators is encouraged for more objective risk assessment. [12] 4. Management of NMIBC 4.1. Intravesical therapy 4.1.1. Low-risk tumors: A single immediate postoperative instillation of mitomycin C or doxorubicin within 24 h (preferably within 6 h) if no suspicion of bladder perforation should be considered. [13] (EL-1). [19] 4.3.4. Annual imaging of upper urinary tract with either CT scan or IVU in high-risk group. 5. Management of muscle invasive bladder cancer 5.1. Radical cystectomy and urinary diversion: 5.1.1. Radical cystectomy is the preferred curative treatment for localized bladder cancer (EL-3). 5.1.2. Radical cystectomy includes removal of regional lymph nodes, the extent of which has not been sufficiently defined (EL-3). 5.1.3. Laparoscopic and robotic radical cystectomy are optional. 5.1.4. Orthotopic bladder or other continent urinary diversion options should be offered to male and female patients lacking any contra-indications. 5.1.5. Neo-adjuvant cisplatin based chemotherapy improved overall survival by 5-7% at 5 years and this option should be offered to patients especially with locally advanced disease (T3, T4) [22] [23] [24] (EL-1). 5.1.6. Follow-up after radical cystectomy:
5.1.6.1. Urine cytology, creatinine and electrolytes blood test every 3-9 months for 2 years and then as clinically indicated. [25] 5.1.6.2. CT chest, abdomen, and pelvis every 3-9 months for 2 years based on risk of recurrence and as clinically indicated. [26] . [27] [Downloaded free from http://www. Ta  N0  M0  Stage 0is  Tis  No  M0  Stage I  T1  N0  M0  Stage II  T2a  N0  M0  T2b  N0  M0  Stage III  T3a  N0  M0  T3b  N0  M0  T4a  N0  M0  Stage IV  T4b  N0  M0  Any T  N1-3  M0  Any T Any N M1 APPENDIX 6.2. Patients with decreased renal function and/or unfit (PS 3) are treated with a combination of carboplatin and gemcitabine or single agent gemcitabine (EL-2). [28] 6.3. Options of second-line chemotherapy include single agent vinflunine (EL-1), [29] and taxanes (LE-2). [30] 6.4. Patients who present with local recurrence may benefit from palliative radiation therapy.
